Search
Trinity Biotech PLC
TRIBAdd to Watchlist
11.670USD
-0.130-1.10%
Close 08-14 16:00（ET）Quotes delayed by 15 min
7.52MMarket Cap
LossP/E TTM
More Details of Trinity Biotech PLC Company
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Trinity Biotech PLC Profile
Ticker SymbolTRIB
Company nameTrinity Biotech PLC
IPO dateOct 21, 1992
CEOGillard (John)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 21
AddressIda Business Park, Bray, Co Wicklow
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code18
Phone01135312955111
Websitehttps://www.trinitybiotech.com/
Ticker SymbolTRIB
IPO dateOct 21, 1992
CEOGillard (John)
Company Executives of Trinity Biotech PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Paul Tivnan
Mr. Paul Tivnan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paul Murphy
Mr. Paul Murphy
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. David Gentry
Mr. David Gentry
IR Contact Officer
IR Contact Officer
--
--
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ronan O'Caoimh
Mr. Ronan O'Caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
FAQs
Who are the top five shareholders of Trinity Biotech PLC?
The top five shareholders of Trinity Biotech PLC are: Mr. Ronan O'Caoimh
How many institutions hold shares of Trinity Biotech PLC (TRIB)?
As of 2026Q1, 50 institutions hold shares of Trinity Biotech PLC, with a combined market value of approximately 876.37K, accounting for 4.33% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2074917.00.
What is the biggest source of revenue for Trinity Biotech PLC?
In 2026Q1, the Clinical Laboratory business generated the highest revenue for Trinity Biotech PLC, amounting to 42.29M and accounting for 74.41% of total revenue.